Retatrutide is a weight loss (glp-1/gip/glucagon) peptide. Typical research dosing is once weekly injection, and the body of supporting research is phase 3 triumph programme.
How to source retatrutide in the Philippines
Retatrutide is still in Phase 3 trials, has no FDA approval anywhere, and is not stocked by any Philippine pharmacy. Buyers source 30mg lyophilized vials through research peptide suppliers shipping cold-chain to NAIA. Always verify a third-party COA per batch before reconstituting.
Retatrutide is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-action mechanism makes it the most potent weight loss compound ever studied in clinical trials.
In the pivotal Phase 3 TRIUMPH-1 trial reported in May 2026, participants on the highest dose (12mg) averaged 28.3% body weight reduction over 80 weeks, rising to 30.3% at 104 weeks in the extension. That is more than double the effect of early GLP-1 drugs. This has made Retatrutide highly sought after in the biohacking and weight loss communities, including in the Philippines.
While not yet FDA approved (currently in Phase 3 trials), research-grade retatrutide is widely available through peptide suppliers. It draws more research interest than any other compound in the incretin class, particularly against semaglutide. Browse all weight loss peptide options to compare, or verify your supplier with the COA verification guide.
GLP-1 Agonism: Activates GLP-1 receptors in the brain and pancreas to suppress appetite, slow gastric emptying, and improve insulin secretion. This is the same mechanism as Ozempic and Mounjaro.
GIP Agonism: Activates GIP receptors which synergize with GLP-1 to enhance insulin response and are thought to reduce the nausea commonly associated with GLP-1 drugs alone.
Glucagon Agonism: This is what makes Retatrutide unique. Glucagon agonism directly increases metabolic rate (thermogenesis) and enhances fat oxidation, particularly visceral fat. This explains the superior weight loss results compared to dual-agonists.
Retatrutide is not commercially available in the Philippines: Eli Lilly's Phase 3 trials are still in progress and no branded product is FDA Philippines-registered. Every retatrutide protocol running in Manila, Makati, BGC, or Cebu in 2026 is research-grade. There is no Mercury Drug or Watsons option for this compound.
The research-grade route runs through the same supplier network that ships semaglutide and tirzepatide. Cold-chain handling is the most critical of the three GLP-class peptides. Retatrutide degrades faster at room temperature, so insulated overnight delivery from a verified local supplier is the only sensible route. Lalamove same-day with a hard-sided cooler is the standard.
Self-directed retatrutide protocols in the Philippines are typically guided by a Salcedo or Legazpi wellness clinic doctor for bloodwork and dose review, even though the prescription itself does not exist. Expect to pay PHP 4,500–8,000 per consult for a doctor with peptide-specific clinical experience. Bloodwork (CBC, CMP, lipid panel, HbA1c) at Hi-Precision or Healthway runs PHP 3,500–5,500.
Makati Medical Center: endocrinology · Makati
Bloodwork and clinical review only; will not prescribe research compounds
St. Luke's Medical Center BGC: wellness medicine · BGC
Some MDs review research peptide protocols informally; no prescription possible
Hi-Precision Diagnostics · Multi-city
Standard pre/post bloodwork; covers Metro Manila, Cebu, Davao
Not applicable: no retail availability · N/A
Retatrutide is Phase 3 only; research-grade is the only Philippines route
| Item | PHP | USD | Source |
|---|---|---|---|
| Research-grade retatrutide 10mg vial | ₱5,500–8,500 | $98–152 | Local supplier with COA, May 2026 |
| Research-grade retatrutide 30mg vial | ₱14,500–19,500 | $260–350 | Bulk pricing, May 2026 |
| Wellness clinic consult (peptide-experienced MD) | ₱4,500–8,000 | $80–143 | Salcedo / Legazpi cluster |
| Pre/post bloodwork panel | ₱3,500–5,500 | $63–98 | Hi-Precision / Healthway |
Customs & import reality
Retatrutide research-grade is treated identically to semaglutide and tirzepatide by BOC: personal-use research quantities are tolerated, commercial quantities are not. Because no branded product exists, customs is unlikely to recognize the compound name; suppliers typically ship invoiced as "research peptide" rather than by chemical name. Cold-chain failures during BOC inspection are the most common loss mode. Verify your supplier's reshipment policy before ordering.
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 2mg | Once weekly | Weeks 1–4 |
| Titration 1 | 4mg | Once weekly | Weeks 5–8 |
| Titration 2 | 8mg | Once weekly | Weeks 9–16 |
| Maintenance | 8–12mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Turning a dose in milligrams into units on a syringe is arithmetic, not judgement. The reconstitution calculator does it for any vial size, and the rest of the calculator set covers cost per milligram and route comparison.
Current local pricing on this compound sits with our partner and supplier: buy retatrutide in the Philippines at 15mg for PHP 3,325, PHP 2,990 with 10% off.
Nausea is common as your body adjusts. Appetite begins to decrease. Some report feeling full very quickly after eating small amounts.
Nausea typically subsides. Food noise begins to quiet. First noticeable weight loss (often 1–3kg) from caloric restriction.
Steady weight loss continues (typically 1–2kg/week when combined with modest dietary improvements). Energy often improves.
Most users report being at or near their maintenance phase. Weight loss slows as body composition improves. Visceral fat reduction becomes visible.
Our partner and supplier
Most readers of this site order from Primara Labs, our partner and supplier. retatrutide 15mg runs ₱3,325 a vial, or ₱2,990 with the standing 10% off, shipped cold-chain from stock already inside the Philippines, batch-numbered on every vial. Metro Manila orders dispatch same day.
View Retatrutide bulk pricingFinished reading and not sure where a 90-day plan would start? Longevity Manila builds one around a single goal, then hands the list to our partner and supplier, Primara Labs.
Retatrutide is not available at any Filipino pharmacy or clinic. It remains a Phase 3 investigational compound globally. Research-grade sourcing is the only path. For Philippines pricing, supplier verification, and COA red flags, see our Retatrutide Philippines 2026 guide. For the legal status of research peptides in the Philippines, see our legality guide. Then work through the supplier checklist.
Citations supporting the clinical claims on this page. Each entry links to the primary record.
Retatrutide Phase 2: obesity
TrialJastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." N Engl J Med 2023;389:514-526.
DOI: 10.1056/NEJMoa2301972Retatrutide Phase 2: type 2 diabetes
TrialRosenstock J et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." Lancet 2023;402(10401):529-544.
DOI: 10.1016/S0140-6736(23)01053-XRetatrutide MASLD trial
TrialSanyal AJ et al. "Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial." Nat Med 2024;30:2037-2048.
DOI: 10.1038/s41591-024-03018-2TRIUMPH-1: Phase 3 pivotal obesity readout
TrialEli Lilly. "Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial." Investor release, 21 May 2026. n=2,339. 12mg: 28.3% at 80 weeks, 30.3% at 104 weeks.
SourceTRIUMPH-4: Phase 3, obesity with knee osteoarthritis
TrialEli Lilly. Investor release, 11 December 2025. n=445, 68 weeks. 12mg: 28.7%. Dysesthesia reported at 20.9% on 12mg against 0.7% on placebo.
SourceTRIUMPH-2 and TRIUMPH-3: Phase 3 readouts and FDA filing plan
TrialEli Lilly. Investor release, 23 July 2026. TRIUMPH-2 (T2D, n=1,152): 20.8%, A1C -1.6%. TRIUMPH-3 (severe obesity with CVD, n=1,949): 22.6%. Lilly plans a BLA submission to the FDA in Q1 2027.
SourceTRIUMPH-1 / TRIUMPH-3: Phase 3 protocols
TrialEli Lilly. "A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Hypertension." ClinicalTrials.gov NCT05882045.
SourceTriple-agonist mechanism review
MechanismCoskun T et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycaemic control and weight loss: From discovery to clinical proof of concept." Cell Metab 2022;34(9):1234-1247.e9.
DOI: 10.1016/j.cmet.2022.07.013Risk · Disclosure · Editorial Status
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
Editorial Status
Independent · Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
September 11, 2026
